The article below presents updated recommendations on newly approved drugs and new safety aspects of immunotherapy for MS – including the risk of infection with COVID-19 and vaccination.
Read the full article here (in English).
Updated recommendations for MS treatment in Switzerland
23.01.2023
Multiple sclerosis (MS) – particularly relapsing-remitting MS (RRMS) – has become a treatable disease in recent decades, and immunotherapies can now influence the long-term progression of the disease.